Which therapeutic conditions is GW Pharmaceuticals initially targeting?
The Directors have selected a number of medical conditions as its initial target markets. These are as follows: • Nerve damage pain and dysfunction, principally Multiple Sclerosis and spinal cord injury; and • Cancer Pain. Further potential markets for the Group’s products include Rheumatoid Arthritis, Stroke/Head Injury, Migraine, Inflammatory Bowel Disease (IBD), Schizophrenia, Epilepsy and Movement Disorders (such as Parkinson’s disease). All of these markets have been selected on the basis of evidence supporting the potential effectiveness of cannabis-based medicines.
